Related Experiment Videos
Drugs in donated blood.
R E Ferner1, J A Dunstan, S Chaplin
1Wolfson Unit of Clinical Pharmacology, Royal Victoria Infirmary, Newcastle upon Tyne.
Lancet (London, England)
|July 8, 1989
Summary
Blood donation safety guidelines are proposed to protect recipients from drug treatments. The guidelines establish recommended waiting periods after the last drug dose for safe blood donation, preventing unnecessary donor deferrals.
Area of Science:
- Pharmacology
- Transfusion Medicine
- Public Health
Background:
- Donated blood from individuals with recent drug treatment poses potential risks to recipients.
- Current guidelines for donor deferral may be overly restrictive, leading to unnecessary rejection of eligible donors.
Purpose of the Study:
- To propose evidence-based guidelines for safe blood donation after drug treatment.
- To minimize the risk of transmitting drug-related adverse effects to blood recipients.
- To reduce the unnecessary deferral of blood donors.
Main Methods:
- Review of pharmacokinetic and pharmacodynamic data for commonly used drugs.
- Analysis of the time required for drug elimination and cessation of potential toxicity.
- Development of a risk-benefit framework for drug-treated blood donors.
Main Results:
- Specific recommended waiting periods between the last drug dose and blood donation for various drug classes.
- Identification of drugs with minimal or no residual risk after a short deferral period.
- Established criteria for safe blood donation balancing donor eligibility and recipient safety.
Conclusions:
- Implementing these guidelines can enhance blood transfusion safety.
- The proposed guidelines aim to optimize donor pool utilization while safeguarding recipients.
- Evidence-based deferral periods are crucial for safe blood donation practices in the context of drug therapy.